Showing 1 - 11 results of 11 for search 'V. V. Babak', query time: 0.02s Refine Results
  1. 1
    Late-onset neutropenia induced by anti-B cell therapy with rituximab in patients with ANCA-associated systemic vasculitis

    Late-onset neutropenia induced by anti-B cell therapy with rituximab in patients with ANCA-associated systemic vasculitis by T. V. Beketova, I. Yu. Popov, V. V. Babak

    Published 2022-06-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Review of guideline for the management of ANCA-associated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis Foundation

    Review of guideline for the management of ANCA-associated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis Foundation by T. V. Beketova, I. Yu. Popov, V. V. Babak

    Published 2021-12-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic

    The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months o... by T. V. Beketova, V. V. Babak, M. D. Suprun

    Published 2021-03-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Ocular Manifestations of COVID-19 in a Patient with ANCAAssociated Vasculitis Treated with Rituximab. A Case Report

    Ocular Manifestations of COVID-19 in a Patient with ANCAAssociated Vasculitis Treated with Rituximab. A Case Report by M. D. Suprun, T. V. Beketova, V. V. Babak, M. D. Evsikova

    Published 2022-07-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Granulomatosis with polyangiitis with severe lung involvement: efficacy of anti-B cell therapy with Rituximab

    Granulomatosis with polyangiitis with severe lung involvement: efficacy of anti-B cell therapy with Rituximab by T. V. Beketova, V. V. Babak, M. D. Suprun, M. D. Evsikova, E. V. Nikolaeva

    Published 2021-07-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    On the issue of post COVID-19 condition in patients with rheumatic diseases

    On the issue of post COVID-19 condition in patients with rheumatic diseases by M. F. Beketova, V. V. Babak, M. D. Suprun, T. V. Beketova, O. A. Georginova

    Published 2022-05-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Avascular necrosis in systemic lupus erythematosus: total hip replacement in a patient with mutation in clotting factor V (Leiden) gene, clinical observation

    Avascular necrosis in systemic lupus erythematosus: total hip replacement in a patient with mutation in clotting factor V (Leiden) gene, clinical observation by F. A. Cheldieva, I. G. Kushnareva, V. V. Babak, A. E. Khramov, T. M. Reshetnyak

    Published 2021-04-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Avascular necrosis as a part of post-COVID syndrome. Case reports

    Avascular necrosis as a part of post-COVID syndrome. Case reports by T. V. Beketova, N. O. Levina, D. O. Ladygina, V. V. Babak, M. F. Beketova, T. N. Krasnova

    Published 2022-09-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Experience with Tixagevimab and Cilgavimab (Evusheld) in 86 rheumatic patients undergoing anti-B cell therapy with rituximab

    Experience with Tixagevimab and Cilgavimab (Evusheld) in 86 rheumatic patients undergoing anti-B cell therapy with rituximab by T. V. Beketova, N. О. Levina, M. V. Dubinskaia, Yu. A. Uskova, I. V. Rozanova, V. V. Babak, M. F. Beketova, T. N. Krasnova

    Published 2023-04-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    The use of the Scleroderma Clinical Trials Consortium Damage Index in systemic sclerosis

    The use of the Scleroderma Clinical Trials Consortium Damage Index in systemic sclerosis by L. P. Ananyeva, V. V. Babak, A. D. Koltakova, O. A. Koneva, O. V. Desinova, M. N. Starovoytova, O. B. Ovsyannikova, R. U. Shayakhmetova

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Pre-exposure prophylaxis of COVID-19 with tixagevimab/cilgavimab (Evusheld) in 63 rituximab-treated patients with ANCA-associated systemic vasculitis: two-year follow-up results

    Pre-exposure prophylaxis of COVID-19 with tixagevimab/cilgavimab (Evusheld) in 63 rituximab-treated patients with ANCA-associated systemic vasculitis: two-year follow-up results by T. V. Beketova, N. O. Levina, Yu. A. Uskova, I. V. Rozanova, M. V. Dubinskaia, S. A. Evdokimova, V. V. Babak, M. F. Beketova, A. V. Devyatkin

    Published 2024-11-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: